R1 RCM 2021 KeyBanc Life Sciences Med Tech Investor Forum

R1 RCM presented at KeyBanc's Life Sciences and Medical Technology Investor Forum on March 23, 2021. The company highlighted its technology-driven revenue cycle management platform with >90% recurring revenue, strong financial performance, and 2021 Adjusted EBITDA growth guidance of $315-330M from $240M in 2020.